Pediatric hereditary angioedema

Pediatric Allergy and Immunology

Volumn 25, Issue 5, 2014, Pages 420-427

  Macginnitie, Andrew J ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Angioedema; Bradykinin; C1 inhibitor; Children; Hereditary angioedema

Indexed keywords

ADRENALIN; AMINOCAPROIC ACID; ANTIHISTAMINIC AGENT; BRADYKININ; COMPLEMENT COMPONENT C1S INHIBITOR; DANAZOL; DIPEPTIDYL CARBOXYPEPTIDASE; ECALLANTIDE; FRESH FROZEN PLASMA; ICATIBANT; KALLIKREIN; STANOZOLOL; STEROID; TRANEXAMIC ACID;

ANGIONEUROTIC EDEMA; BLOOD VESSEL PERMEABILITY; CHILDHOOD; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); EMERGENCY TREATMENT; ENDOTHELIUM CELL; GENE MUTATION; HUMAN; IMMUNOPATHOGENESIS; LIFESTYLE; PATHOPHYSIOLOGY; PATIENT COUNSELING; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; REVIEW; TREATMENT PLANNING; CHILD;

ANGIOEDEMAS, HEREDITARY; CHILD; HUMANS;

EID: 84907598749     PISSN: 09056157     EISSN: 13993038     Source Type: Journal    
DOI: 10.1111/pai.12168     Document Type: Review

References (66)

1. Quincke H. Original reports: on acute localized cutaneous dropsy. Appl Dermatol Mon 1882: 1: 129-31.
2. Osler W. Hereditary angio-neurotic oedema. Am J Med Sci 1888: 95: 362-7.
3. Zuraw BL. Clinical practice: hereditary angioedema. N Engl J Med 2008: 359: 1027-36.
4. Winnewisser J, Rossi M, Spath P, Burgi H. Type I hereditary angio-oedema. Variability of clinical presentation and course within two large kindreds. J Intern Med 1997: 241: 39-46.
5. Bowen T, Cicardi M, Farkas H, et al. 2010 international consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010: 6: 24-36.
6. Cicardi M, Bork K, Caballero T, et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: a consensus report of an international working group. Allergy 2012: 67: 147-57.
7. Craig T, Pursun EA, Bork K, et al. WAO guideline for the management of hereditary angioedema. WAO J 2012: 5: 182-99.
8. Wahn V, Aberer W, Eberl W, et al. Hereditary angioedema (HAE) in children and adolescents-a consensus on therapeutic strategies. Eur J Pediatr 2012: 171: 1339-48.
9. Lang DM, Aberer W, Bernstein JA, et al. International consensus on hereditary and acquired angioedema. Ann Allergy Asthma Immunol 2012: 109: 395-402.
10. Davis AE III. C1 inhibitor and hereditary angioneurotic edema. Ann Rev Immunol 1988: 6: 595-628.
11. Davis AE III. The pathophysiology of hereditary angioedema. Clin Immunol 2005: 114: 3-9.
12. Landerman NS, Webster ME, Becker EL, Ratcliffe HE. Hereditary angioneurotic edema II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein. J Allergy 1962: 33: 330-41.
13. Donaldson VH, Evans RR. A biochemical abnormality in hereditary angioedema: absence of serum inhibitor of C'1-esterase. Am J Med 1963: 35: 37-44.
14. Rosen FS, Charache J, Pensky J, Donaldson V. Hereditary angioneurotic edema: two genetic variants. Science 1965: 148: 957-8.
15. Pappalardo E, Cicardi M, Duponchel C, et al. Frequent de novo mutations and exon deletions in the C1inhibitor gene of patients with angioedema. J Allergy Clin Immunol 2000: 106: 1147-54.
16. Blanch A, Roche O, Urrutia I, et al. First case of homozygous C1 inhibitor deficiency. J Allergy Clin Immunol 2006: 118: 1330-5.
17. Buyukozturk S, Eroglu BK, Gelincik A, et al. A Turkish family with a novel mutation in the promoter region of the C1 inhibitor gene. J Allergy Clin Immunol 2009: 123: 962-4.
18. Lopez-Lera A, Favier B, de la Cruz RM, Garrido S, Drouet C, Lopez-Trascasa M. A new case of homozygous C1-inhibitor deficiency suggests a role for Arg378 in the control of kinin pathway activation. J Allergy Clin Immunol 2010: 126: 1307-11.
19. Bork K, Meng G, Staubach P, Jardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006: 119: 267-74.
20. Matesic D, Perez ERF, Vlahakis NE, Hagan JB. Acute pancreatitis due to hereditary angioedema. Ann Allergy Asthma Immunol 2006: 97: 611-4.
21. Prematta MJ, Bewtra AK, Levy RJ, et al. Per-attack reporting of prodromal symptoms concurrent with C1-inhibitor treatment of hereditary angioedema attacks. Adv Ther 2012: 29: 913-22.
22. Ricketti AJ, Cleri DJ, Ramos-Bonner LS, Vernaleo JR. Hereditary angioedema presenting in late middle age after angiotensin-converting enzyme inhibitor treatment. Ann Allergy Asthma Immunol 2007: 98: 397-401.
23. Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol 2012: 130: 692-7.
24. Grumach AS, Valle SOR, Toledo E, et al. Hereditary angioedema: first report of the Brazilian registry and challenges. J Eur Acad Dermatol Venereol 2012: 27: e338-44.
25. Pedrosa M, Caballero T, Gomez-Traseira C, Olveira A, Lopez-Serrano C. Usefulness of abdominal ultrasonography in the follow-up of patients with hereditary C1-inhibitor deficiency. Ann Allergy Asthma Immunol 2009: 102: 483-6.
26. Donaldson VH, Rosen FS. Hereditary angioneurotic edema: a clinical survey. Pediatrics 1966: 37: 1017-27.
27. Farkas H. Pediatric hereditary angioedema due to C1-inhibitor deficiency. Allergy Asthma Clin Immunol 2010: 6: 18-27.
28. Bygum A, Fagerberg CR, Ponard D, Monnier N, Lunardi J, Drouet C. Mutational spectrum and phenotypes in Danish families with hereditary angioedema because of C1 inhibitor deficiency. Allergy 2011: 66: 76-84.
29. Roche O, Blanch A, Caballero T, Sastre N, Callejo D, Lopez-Trascasa M. Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. Ann Allergy Asthma Immunol 2005: 94: 498-503.
30. Elhachem C, Amiour M, Guillot M, Laurent J. Hereditary angioneurotic edema: a case report in a 3-year-old child. Arch Pediatr 2005: 12: 1232-6.
31. Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson DA, Horn PT. The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc 2010: 31: 407-14.
32. Bewtra AK, Levy RJ, Jacobson KW, Wasserman RL, Machnig T, Craig TJ. C1-inhibitor therapy for hereditary angioedema attacks: prospective patient assessments of health-related quality of life. Allergy Asthma Proc 2012: 33: 427-31.
33. Tarzi MD, Hickey A, Forster T, Mohammadi M, Longhurst HJ. An evaluation of tests used for the diagnosis and monitoring of C1 inhibitor deficiency: normal serum C4 does not exclude hereditary angio-edema. Clin Exp Immunol 2007: 149: 513-6.
34. Kelemen Z, Moldovan D, Mihaly E, et al. Baseline level of functional C1-inhibitor correlates with disease severity scores in hereditary angioedema. Clin Immunol 2010: 134: 354-8.
35. Nielsen EW, Thidemann H, Holt JJ, Mollnes TE. C1 inhibitor and diagnosis of hereditary angioedema in newborns. Pediatr Res 1994: 35: 184-7.
36. Jacobs J. Recurrent attacks of hereditary angioedema: a case of delayed diagnosis. Allergy Asthma Proc 2011: 32: S23-6.
37. Gower RG. HAE update: determining optimal patient specific therapy. Allergy Asthma Proc 2013: 32: 7-12.
38. Zuraw BL. Current and future therapy for hereditary angioedema. Clin Immunol 2005: 114: 10-6.
39. Gelfand JA, Serins RJ, Alling DW, Frank MM. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med 1976: 295: 1444-8.
40. Banerji A, Sloane DE, Sheffer AL. Hereditary angioedema: a current state-of-the-art review, V: attenuated androgens for the treatment of hereditary angioedema. Ann Allergy Asthma Immunol 2008: 100: S19-22.
41. Thoufeeq MH, Ishtiaq J, Abuzakouk M. Danazol-induced hepatocellular carcinoma in a patient with hereditary angioedema. J Gastrointest Cancer 2012: 43: 280-2.
42. Farkas H, Harmat G, Fust G, Varga L, Visy B. Clinical management of hereditary angio-oedema in children. Pediatr Allergy Immunol 2002: 13: 153-61.
43. Tappeiner G, Hintner H, Glatzl J, Wolff K. Hereditary angio-oedema: treatment with danazol: report of a case. Br J Dermatol 1979: 100: 207-12.
44. Barakat A, Castaldo AJ. Hereditary angioedema: danazol therapy in a 5-year old child. Am J Dis Child 1993: 147: 931-2.
45. Sheffer AL, Austen KF, Rosen FS. Tranexamic acid therapy in hereditary angioneurotic edema. N Engl J Med 1972: 287: 452-4.
46. Farkas H, Csuka D, Zotter Z, Varga L, Fust G. Prophylactic therapy in children with hereditary angioedema. J Allergy Clin Immunol 2013: 131: 579-82.
47. Prematta M, Gibbs JG, Pratt EL, Stoughton TR, Craig TJ. Fresh frozen plasma for the treatment of hereditary angioedema. Ann Allergy Asthma Immunol 2007: 98: 383-8.
48. Craig TJ, Levy RL, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema. J Allergy Clin Immunol 2009: 124: 801-8.
49. Craig TJ, Bewtra AK, Bahna SL, et al. C1 esterase inhibitor concentrate in 1085 hereditary angioedema attacks-final results of the I.M.P.A.C.T. 2 study. Allergy 2011: 66: 1604-11.
50. Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010: 363: 513-22.
51. Zuraw BL, Kalfus I. Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. Am J Med 2012: 125: 938.e1-7.
52. Farkas H, Csuka D, Zotter Z, et al. Treatment of attacks with plasma derived C1-inhibitor concentrate in pediatric hereditary angioedema patients. J Allergy Clin Immunol 2013: 131: 909-11.
53. Schneider L, Hurewitz D, Wasserman R, et al. C1-INH concentrate for treatment of acute hereditary angioedema: a pediatric cohort from the I.M.P.A.C.T. studies. Pediatr Allergy Immunol 2013: 24: 54-60.
54. Lumry W, Manning ME, Hurewitz DS, et al. Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children. J Pediatr 2013: 162: 1017-22.
55. Zuraw B, Cicardi M, Levy RJ, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 2010: 126: 821-7.
56. Moldovan D, Reshef A, Fabiani J, et al. Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension study. Clin Exp Allergy 2012: 42: 929-35.
57. Hack CE, Relan A, Baboeram A. Immunosafety of recombinant human C1-inhibitor in hereditary angioedema: evaluation of IgE antibodies. Clin Drug Investig 2013: 33: 275-81.
58. Cicardi M, Levy RL, McNeil DL, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 2010: 363: 523-31.
59. Levy RJ, Lumry WR, McNeil DL, et al. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol 2010: 104: 523-9.
60. Lumry WR, Bernstein JA, Li HH, et al. Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study. Allergy Asthma Proc 2013: 34: 155-61.
61. Dyax Corp. Kalbitor [package insert]. Cambridge, MA: Dyax Corp; December 2009.
62. MacGinnitie AJ, Davis-Lorton M, Stolz LE, Tachdjian R. Use of ecallantide in pediatric hereditary angioedema. Pediatrics 2013: 132: e490-7. doi: 10.1542/peds.2013-0646.
63. Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010: 363: 532-41.
64. Lumry WR, Li HH, Levy RJ, et al. Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol 2011: 104: 523-9.
65. Cole SW, Lundquist LM. Icatibant for the treatment of hereditary angioedema. Ann Pharmacother 2013: 47: 49-55.
66. Farkas H, Zotter Z, Csuka D. Short-term prophylaxis in hereditary angioedema due to deficiency of the C1-inhibitor-a long-term survey. Allergy 2012: 67: 1586-93.